Pharmacodynamics of a long acting depot preparation of avorelin in patients with prostate cancer

Journal of Urology

Volumn 162, Issue 6, 1999, Pages 2019-2023

  Kaisary, Amir V ^a   Bowsher, Winsor G ^b   Gillatt, David A ^c   Anderson, John B ^e   Malone, Peter R ^d   Imbimbo, Bruno P ^h   Ryan, Audrey M ^a   Sandhu, S S ^a   Simmonds, Nick R ^a   Norman, Joanne ^b   Husband, Wendy ^b   Gould, Heather ^c   Salter, Liz ^c   McCullagh, Angela ^d   Burden, Kate ^d   Brown, Michelle ^e   Harrington, Marian ^e   Ducroq, David H ⁱ   Turkes, Atilla ^f   Cartwright Taylor, Lesley ^g   Ong, Huy ⁱ   Cesana, Marina ^h   Maggi, Tony ^h   Iannacone, Claudio ^h   more..

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b ROYAL GWENT HOSPITAL   (United Kingdom)

^c SOUTHMEAD HOSPITAL   (United Kingdom)

^d Battle Hospital   (United Kingdom)

^e ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^f Tenovus Institute   (United Kingdom)

^g Europharm Ltd   (United Kingdom)

^h Mediolanum Farmaceutici   (Italy)

ⁱ NONE

Author keywords

Gonadorelin; Prostatic neoplasms; Testosterone

Indexed keywords

AVORELIN; GONADORELIN RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; GONADORELIN RELEASE; GONADOTROPIN RELEASE; HORMONAL REGULATION; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RECEPTOR AFFINITY; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032702302     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)68091-3     Document Type: Article

References (17)

1. Parker, S. L., Tong, T., Bolden, S. and Wingo, P. A.: Cancer statistics, 1997. CA, 47: 5, 1997.
2. Byar, D. P. Proceedings: the Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer, 32: 1126, 1973.
3. Prostate Cancer Trialists' Collaborative Group: Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet, 346: 265, 1995.
4. Peeling, W. B.: Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma. Urology, suppl., 33: 45, 1989.
5. The Leuprolide Study Group: Leuprolide versus diethylstilbestrol for metastatic prostatic cancer. New Engl. J. Med., 311: 1281, 1984.
6. Eisenberger, M. A., Simon, R., O'Dwyer, P. J., Wittes, R. E. and Friedman, M. A.: A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J. Clin. Oncol., 3: 827, 1985.
7. Deghenghi, R., Boutignon, F., Wüthrich, P. and Lenaerts, V.: Properties of 2-methyl-tryptophan and biological activity of 2-me-trp containing peptides. 3rd Forum on Peptides and Proteins, Biarritz, France, March 22-26, 1993.
8. Boutignon, F., Touchet, H., David, S., Wüthrich, P., Deghenghi, R., Ong, H., Dubuc, M., Cesana, M. and Maggi, T.: Protracted release of the LHRH agonist Avorelin (MF6001) from two depot formulations in dogs and men. Letters. Peptide Sci., 4: 423, 1997.
9. Hudon, E., Rondeau, J. J., Lenaerts, V., Würthrich, P., Boutignon, F., Deghenghi, R., Marleau, S., Yamaguchi, N., Adam, A. and Ong, H.: Radioimmunoassay of meterelin and pharmacokinetics after single injection and implant administration in dogs. J. Pharm. Sci., 86: 172, 1997.
10. Gleason, D. F.: Histologic grading and clinical staging of rostatic carcinoma. In: Urologic Pathology: The Prostate. Edited by M. Tannenbaum. Philadelphia: Lea & Febiger, pp. 171-197, 1977.
11. Beahrs, O. H., Henson, D. E., Hutter, R. V. P. and Kennedy, B. J.: Manual for Staging of Cancer, 4th ed. Philadelphia: Lippincott, chapt. 31, pp. 181-186, 1992.
12. Tyrrell, C. J., Altwein, J. E., Klippel, F., Varenhorst, E., Lunglmayr, G., Boccardo, F., Holdaway, I. M., Haefliger, J.-M., Jordaan, J. P. and Sotarouta, M. for the International Prostate Cancer Study Group: A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer. J. Urol., 146: 1321, 1991.
13. Aaronson, N. K.: The assessment of subjective response in prostatic cancer clinical research. Amer. J. Clin. Oncol., suppl., 11: S43, 1988.
14. WHO Collaborating Centre for International Drug Monitoring. WHO Adverse Reaction Dictionary. 1995.
15. Leo, M. E., Bilhartz, D. L., Bergstralh, E. J. and Oesterling, J. E.: Prostate specific antigen in hormonally treated stage D2 prostate cancer: is it always an accurate indicator of disease status? J. Urol., 145: 802, 1991.
16. Miller, J. I., Ahmann, F. R., Drach, G. W., Emerson, S. S. and Bottaccini, M. R.: The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. J. Urol., 147: 956, 1992.
17. Ismail, M. and Gomella, L. G.: Current treatment of advanced prostate cancer. Tech. Urol., 3: 16, 1997.